BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Diopsys Inc. to Introduce OCT Enhancement Software


9/5/2012 10:01:15 AM

PINE BROOK, N.J., Sept. 4, 2012 /PRNewswire/ -- Eye care providers will soon have a new option for improving the analysis of their current Optical Coherence Tomography (OCT) images. The new Diopsys® CORDA software uses existing OCT images to give eye care professionals a better understanding of the health of the Retinal Nerve Fiber Layer (RNFL).

According to literature, current algorithms in OCT technology may overstate the RNFL thickness due to patient physiology and other test related limitations. The Diopsys® CORDA software utilizes existing images to better discriminate different components, leading to a more accurate assessment of the RNFL.

Diopsys has finalized the CORDA software with input from Wills Eye Institute of Philadelphia. A recent poster presented at The Association for Research in Vision and Ophthalmology (ARVO) conference concluded that the CORDA software correlates well with RNFL thickness which helps to better detect glaucomatous changes on OCT images. Alberto Gonzalez, MD, Research Director for Diopsys says, "The Diopsys® CORDA software will improve the analysis of OCT images, helping doctors detect vision disorders earlier so treatment can begin sooner."

The new CORDA software will afford eye care specialists the ability to greatly enhance the clinical utility of their existing OCT devices without investing in costly hardware upgrades. Diopsys® CORDA has been proven to work with existing OCT images from Carl Zeiss, Meditec, Heidelberg Engineering, Optovue and Topcon devices.

To be added to a contact list for further information on the release of the Diopsys® CORDA software, please visit www.diopsys.com/CORDAinfo.

About Diopsys

Diopsys, Inc. (www.diopsys.com) is a medical instrumentation company dedicated to delivering high-quality, cost-effective preventative health care solutions. The company specializes in the development and marketing of patient-friendly, non-invasive vision testing devices utilizing Visual Evoked Potential (VEP) technology.

SOURCE Diopsys, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES